David Domzalski

CEO & President

David Domzalski serves as the President of our U.S. subsidiary, Foamix Pharmaceuticals Inc., and has been with us since April 2014. Mr. Domzalski has 20 years of industrial experience, previously holding positions as Vice President Sales and Marketing at LEO Pharma Inc. from 2009 to July 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President Sales and Marketing at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania.

Ilan Hadar

Country Manager & CFO

Ilan Hadar has served as our Chief Financial Officer since February 2014. Mr. Hadar has 18 years of experience in executive financial positions, previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager,Accounting and Reporting at the Israeli subsidiary of HP from 2007 to 2011, and prior to that as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a B.A. in business administration and economics and an MBA from The Hebrew University of Jerusalem.

Yohan Hazot


Yohan Hazot has served as our Chief Technology Officer since December 2014. Mr Hazot has been with us since April 2007 in several positions in the field of drug development and intellectual property, and lately held the position of Director of Pharmaceutical Development. Mr Hazot holds an MSc in Biochemistry & Biotechnology from the National Institute of Applied Sciences,  Lyon, France and is the inventor of several patents in the field of pharmaceutical chemistry.

David Schuz

Executive Vice President, Intellectual Property

David Schuz has served as our Executive Vice President since 2010 and as our Senior Vice President, for intellectual property since July 2006. Mr. Schuz has 20 years of experience in the field of intellectual property in relation to the pharmaceuticals and biotechnology industries, previously holding various intellectual property and legal positions at Biotechnology General Israel Ltd. and Savient Pharmaceuticals, Inc. between 1996 and 2006, including Vice President from 2003. Mr. Schuz holds an LL.M. from the London School Economics; a Certificate in Patent Law, Queen Mary London University; an M. Phil. (Biochemistry), and a Diploma of Pharmacology, both from Cambridge University; and a B.Sc. Hons. (Chemistry) from Manchester University.

Dr. Mitchell Shirvan

Sr. Vice President, Innovative R&D

Mitchell Shirvan, Ph.D., has served as our Senior Vice President of Research and Development since March 2014. Dr. Shirvan has over 20 years of experience in the pharmaceuticals and biotechnology industry, previously holding positions of Chief Executive Officer at Macrocure Ltd. from 2008 to 2012 and as Senior Director, Strategic Business Planning and Senior Manager, Research and Development at Teva Pharmaceutical Industries between 1992 and 2008. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem, and an MBA from the University of Bradford.

Yael Fund-Gross

Finance Director

Yael Fund-Gross has served as our Finance Director since July 2017. Mrs. Fund-Gross has been with us since October 2014 and Prior to her role as Finance Director she served as Controller of the company. Previously she held a position as Manager at KPMG-Somekh Chaikin accounting firm. Mrs Fund-Gross holds a B.A in Accounting and Economics from the Bar-Ilan University and an MBA from Tel-Aviv University. 

Dr. Russell Elliott

Vice President of Drug Development

Previously served as Head of Skincare Technology at Lonza Inc, responsible for development of next generation skincare actives.  Also served as Head of Product Development at Stiefel, a GSK Company, leading development efforts in bringing to market several products including Sorilux, Fabior, Panoxyl Foams, and a range of consumer products for Stiefel’s global market.  He was head of the Center of Excellence for Liquids, Cream and Ointments at GSK based in UK from Feb 2007 until 2011.  In this role, Russell was responsible for transforming the scientific capabilities of manufacturing as well as leading the technical integration of Stiefel’s large product portfolio into the GSK supply chain.  Russell started his career at Procter & Gamble from 1992 until 2007 where as a principal scientist he was responsible for the development of highly consumer preferred products for Olay and other major global brands.  He has filed more than 60 patent applications in the area of skincare formulation.  Russell has a PhD and MA from The University of Oxford and is a Fellow of the Royal Society of Chemistry.  

Dr. Herman Ellman

Vice President, Clinical Development

Herman Ellman, M.D., has served as our Vice President of Clinical Development since April 2014. Dr. Ellman has over 25 years of experience in the pharmaceutical industry, previously holding positions as Senior Vice President for Clinical Development at Warner Chilcott from 2000 to 2013 and Medical Director at Berlex Laboratories from 1995 to 2000. Dr. Ellman holds a M.D. from the State University of New York, Downstate Medical Center and Boards in Internal Medicine, Pulmonary Diseases and Critical Care Medicine.

Alvin Howard

Vice President, Regulatory Affairs

Alvin Howard has served as our Vice President of Regulatory Affairs since April 2014. Mr. Howard has over 30 years of industry experience, previously holding positions as Senior Vice President of Regulatory Affairs in Warner Chilcott from 2005 to 2013, Vice President of Regulatory Affairs at Roberts Pharmaceuticals from 1998 to 2000 and various positions at Solvay Pharmaceuticals from 1990 to 1998. Mr. Howard holds a B.Sc. in chemistry from Stillman College, Tuscaloosa, Alabama.

Dr. Iain Stuart

Vice President of Clinical Development

Over 18 years of product development experience in multiple therapeutic classes with the last 8 years being focused exclusively in dermatology.  Served as Vice President of Medical Strategy and Scientific Affairs at LEO Pharma, Inc. responsible for all post-marketing medical support to the company’s product lines in actinic keratosis and psoriasis.  Responsible for the late-stage clinical development of Enstilar® aerosol foam, and for the first wave of follow-on global approvals of Picato®.  Also served as Director, Clinical Operations – The Americas, Vice President of LEO Project Management, and Director of Preclinical Development, all at LEO Pharma with the latter two being based in LEO Pharma’s Danish HQ.  Iain’s career began at the preclinical CRO, Inveresk Research (now Charles River) as a Senior Study Director, and following this spent 7 years working in oncology and auto-immune diseases at Cyclacel, Inc. in various roles culminating in Project Manager, Pharmaceutical Development.  Iain has a PhD and 1st Class Honors BSc. in Chemistry from Glasgow Caledonian University and was a Post-doctoral Fellow in Medicinal Chemistry at the University of Strathclyde.